Form 4: BDTX CMO Granted 250,000 Stock Options

Black Diamond Therapeutics' Chief Medical Officer, Sergey Yurasov, was granted 250,000 stock options with an exercise price of $2.57, vesting over four years.

Summary

• Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics, Inc. (BDTX), was granted 250,000 stock options.
• The options have an exercise price of $2.57 per share.
• The grant date for these options was January 21, 2026.
• The options will vest over a four-year period: 25% on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
• Vesting is contingent upon Mr. Yurasov's continued service to the company.
• The expiration date for these options is January 20, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard compensation practice designed to align management incentives with shareholder interests, reflecting ongoing commitment. It is a neutral-to-slightly-positive event for the company's governance and executive retention.

Positives

• The grant of 250,000 stock options aligns the Chief Medical Officer's long-term incentives with shareholder value creation.
• The vesting schedule encourages continued service and commitment from a key executive.

Future Outlook

The options will vest over a four-year period, with 25% vesting on January 21, 2027, and the remainder in 36 equal monthly installments thereafter, contingent on continued service.

Industry Context

The grant of stock options to a Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages to attract, retain, and incentivize top talent.

Comparison to Industry Standards

• Executive stock option grants are a common compensation tool across the biotech sector, similar to practices at companies like Moderna, Biogen, or Vertex Pharmaceuticals, which frequently use equity awards to align executive interests with long-term company performance.
• The vesting schedule, typically over three to five years, is consistent with industry norms designed to encourage executive retention and sustained performance.

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of options, but also benefits from enhanced executive incentive and alignment with long-term company performance.
• Executive (Sergey Yurasov): Receives a significant equity award, increasing personal stake and potential wealth tied to company success.

Next Steps

• The options will begin vesting on January 21, 2027, with subsequent monthly vesting installments.

Key Dates

Keywords

BDTX, Black Diamond Therapeutics, stock options, Sergey Yurasov, Chief Medical Officer, executive compensation, Form 4